Clinical treatment has become popular abroad, and many clinical projects have even been snatched away as soon as they come out. Due to the misunderstanding of clinical practice in China, many patients who need clinical practice have not paid attention to clinical information in a timely manner. For cancer patients who have no cure at this stage, you might as well pay attention to new clinical drugs!
M7824 Introduction
M7824 can inhibit PD-L1 protein ligand and inhibit the TGF-β pathway. It is a two-pronged approach and can promote the killing of immune cells on tumor cells.
New drug is a project participated in by the famous Grade A hospital Sichuan University West China Hospital , and is responsible for the famous professor Director Gou Hongfeng!
indications
M7824 can be used for multi-cancer treatment such as: lung cancer, gallbladder cancer , uterine cancer, cervical cancer , etc.
patients who want to have a clinical diagnosis can come to me and receive front-line precise treatment. There are not many places, and the hospital will bear the financial burden of treatment!
Usage Dosage
Dosage form: Injection
Specifications: 600mg/60ml
Usage Dosage: 1200mg, once every two weeks or 2400mg, once every three weeks
Drug use schedule: single dose, once every two weeks or once every three weeks
Shenyan Hospital Public announcement
This project is a new drug project in clinical practice in many countries, and the efficacy and safety are greatly guaranteed!
